CLINICAL_TRIALS ClinicalTrials.gov record update

PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02023905
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:51.435526+00:00
Published At: 2022-12-29T00:00:00+00:00
Record Updated At: 2022-12-29
Results Posted At: 2022-12-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Low Grade Glioma", "World Health Organization (WHO) Grade II Astrocytomas", "Oligodendrogliomas", "Mixed Oligoastrocytomas"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-12-29"
protocolSection.identificationModule.nctId: "NCT02023905"
protocolSection.identificationModule.officialTitle: "PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-12-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.